These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25130956)

  • 1. Association of sociodemographic factors and prostate-specific antigen (PSA) testing.
    Gorday W; Sadrzadeh H; de Koning L; Naugler C
    Clin Biochem; 2014 Nov; 47(16-17):164-9. PubMed ID: 25130956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
    Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
    Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
    Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
    Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Antigen Test Utilization in a Major Canadian City.
    Wang Q; Chen F; Jiang D; Kabani A; Sokoro AAH
    Am J Clin Pathol; 2020 May; 153(6):776-780. PubMed ID: 32003789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
    Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
    Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of prostate cancer screening in a UK region.
    Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
    BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines.
    Jackson BR; Roberts WL
    J Gen Intern Med; 2005 Sep; 20(9):859-61. PubMed ID: 16117757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sociodemographic correlates of fecal immunotesting for colorectal cancer screening.
    Crouse A; Sadrzadeh SM; de Koning L; Naugler C
    Clin Biochem; 2015 Feb; 48(3):105-9. PubMed ID: 25500418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
    Jønler M; Eddy B; Poulsen J
    Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men.
    McGregor SE; Bryant HE; Brant RF; Corbett PJ
    Chronic Dis Can; 2002; 23(3):111-9. PubMed ID: 12443567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral associations between prostate and colon cancer screening.
    Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
    J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sociodemographic correlates of urine culture test utilization in Calgary, Alberta.
    Griener TP; Naugler C; Chan WW; Church DL
    BMC Urol; 2018 Jan; 18(1):2. PubMed ID: 29310636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
    Merrill RM
    Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.